Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed,high-risk,locally advanced cervical cancer(ENGOT-cx11/GOG-3047/KEYNOTE-A18):a randomised,double-blind,phase 3 clinical trial